Yahoo Finance Sarepta Therapeutics' Michael Chambers Acquires 19% More Stock
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shareholders (or potential shareholders) will be happy to see that insider Michael Chambers recently bought a whopping US$3.7m worth of stock, at a price of US$106. Not only is that a big swing, but it increased their holding size by 19%, which is definitely great to see.
Check out our latest analysis for Sarepta Therapeutics
Sarepta Therapeutics Insider Transactions Over The Last Year
In fact, the recent purchase by insider Michael Chambers was not their only acquisition of Sarepta Therapeutics shares this year. They previously made an even bigger purchase of US$6.0m worth of shares at a price of US$105 per share. So it's clear an insider wanted to buy, at around the current price, which is US$108. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. The good news for Sarepta Therapeutics share holders is that an insider was buying at near the current price. Michael Chambers was the only individual insider to buy during the last year.
Michael Chambers bought a total of 138.14k shares over the year at an average price of US$106. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Sarepta Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It's great to see that Sarepta Therapeutics insiders own 4.3% of the company, worth about US$430m. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
What Might The Insider Transactions At Sarepta Therapeutics Tell Us?
It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. Once you factor in the high insider ownership, it certainly seems like insiders are positive about Sarepta Therapeutics. Nice! While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we found 2 warning signs for Sarepta Therapeutics that deserve your attention before buying any shares.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
